Meta-Analysis



Journal of International Medical Research 2016, Vol. 44(6) 1182–1190 © The Author(s) 2016 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0300060516671623 imr.sagepub.com

Effect of dexmedetomidine on postoperative cognitive dysfunction in elderly patients after general anaesthesia: A meta-analysis

Chengmao Zhou^{1,2}, Yu Zhu², Zhen Liu¹ and Lin Ruan¹

Abstract

Objective: We undertook a meta-analysis to investigate the effect of dexmedetomidine on postoperative cognitive dysfunction (POCD).

Methods: We searched PubMed, EMBASE, the Cochrane Library, CNKI and Google Scholar to find randomized controlled trials (RCTs) of the influence of dexmedetomidine on POCD in elderly adults who had undergone general anaesthesia. Two researchers independently screened the literature, extracted data, and evaluated methodologic quality against inclusion and exclusion criteria. We used RevMan 5.2 to undertake our meta-analysis.

Results: Thirteen RCTs were included. Compared with controls, dexmedetomidine: 1) significantly reduced the incidence of POCD (relative risk = 0.59, 95% confidence interval [CI] 0.45–2.95) and improved Mini-Mental State Examination (MMSE) score (mean difference, MD = 1.74, 95% CI 0.43–3.05) on the first postoperative day; and 2) reduced the incidence of POCD after the first postoperative day (MD = 2.73, 95% CI 1.33–4.12).

Conclusion: Dexmedetomidine reduces the incidence of POCD and improves postoperative MMSE score.

Keywords

Response: dexmedetomidine, general anesthesia, cognitive function, meta-analysis, RCT, POCD

Date received: 6 June 2016; accepted: 7 September 2016

Postoperative cognitive dysfunction (POCD) is one of the most common complications affecting the central nervous system after general anaesthesia, especially in elderly patients. Its clinical manifestations include cognitive function disorder, personality change and memory impairment; in severe ¹Department of Anesthesiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China ²Zhaoqing Medical College, Zhaoqing, China

Corresponding author:

Lin Ruan, Department of Anesthesiology, Affiliated Tumor Hospital of Guangxi Medical University, River Road No. 71, Nanning, Guangxi, China. Email: RuanLin187@163.com

Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us. sagepub.com/en-us/nam/open-access-at-sage). cases, Alzheimer's disease (AD) may occur. Postoperative cognitive dysfunction can prolong recovery from surgery and impair quality of life in the longer term. The Mini Mental State Examination (MMSE) is commonly used to evaluate cognitive function postoperatively. For patients over the age of 60 years, POCD can reportedly be identified in 25.8% of cases 1 week after surgery and in 9.9% of cases 3 months after surgery. Consequently, POCD has become a crucial concern for anaesthesiologists; however, the mechanism by which anaesthesia might provoke POCD and the influence of different modes of anaesthesia on the incidence of POCD remain unclear.

Dexmedetomidine, a highly selective $\alpha 2$ adrenoceptor agonist, mainly acts in the locus coeruleus to cause sedation. It also has analgesic properties. The use of dexmedetomidine in the conduct of anaesthesia for the elderly is becoming increasingly popular, as it has been reported to reduce the risk of POCD. Nevertheless, there is also a body of evidence that calls the efficacy of dexmedetomidine into question, and its role in anaesthesia for the elderly remains a matter of lively debate. We undertook a meta-analysis to examine the efficacy of dexmedetomidine for the prevention of POCD in elderly patients, so as to inform future clinical decision making.

Materials and methods

Inclusion and exclusion criteria

We identified randomized controlled trials (RCTs) of patients undergoing surgery under general anaesthesia. The intervention in the experimental group was a single or continuously-administered intravenous dose of dexmedetomidine before and during anaesthesia; the control groups received an intravenous injection of placebo. The main outcome indicator in eligible studies was the incidence of cognitive dysfunction on and after the first postoperative day, and MMSE

score on the first postoperative day. We excluded studies that lacked specific exclusion data or with only figures and tables, duplicate publications, studies that used formulations of dexmedetomidine that are not widely available, studies with incomplete information or data, and articles for which we could not obtain the full text.

Search strategy

We searched PubMed, EMBASE, the Cochrane Library, China Academic Journals full-text database (CNKI) and Google Scholar to find relevant RCTs. For PubMed, a combination of subject terms and free text was adopted for the search thus: ("dexmedetomidine" [MeSH Terms] OR "dexmedetomidine" [All Fields]) AND cognitive ("postoperative dysfunction" [MeSH Terms] OR ("postoperative" [All Fields] AND "cognitive dysfunction" [All Fields] OR "postoperative cognitive dysfunction" [All Fields] OR "POCD" [All Fields]) AND ("general anaesthesia" [MeSH Terms] OR "general anaesthesia" [All Fields]). Search terms for other databases included "dexmedetomidine", "postoperative cognitive dysfunction", "POCD" and "general anaesthesia". The search dates ranged from the establishment of each database to June 2016.

Literature screening, data extraction and quality assessment

Two researchers independently screened the literature, extracted data and evaluated the methodologic quality of the studies identified. We evaluated methodologic quality of the RCTs identified using a modified Jadad scale. Evaluation included randomization, allocation concealment, and blinding of implementers and participants. The two researchers resolved disagreements by discussion or consulted a third party when consensus could not be reached. A data extraction table was employed to extract data. Table 1 shows the extracted contents and Jadad scores.

Statistical analysis

We used RevMan 5.2 to conduct the metaanalysis. For dichotomous data, odds ratios (ORs) with 95% confidence intervals (CIs) were used to express effect-size, while mean difference (MD) and 95% CIs were used for continuous data. First, we conducted a heterogeneity test (significance level $\alpha = 0.10$) on included studies using the χ^2 test, and judged the extent of heterogeneity in combination with the I^2 test. A fixed effects model was used to conduct the meta-analysis if no heterogeneity (P > 0.1 and $I^2 < 50.0\%$) was found among the studies. If significant heterogeneity (P < 0.1 or $I^2 > 50.0\%$) was identified, we sought its source. For studies with significant clinical heterogeneity, subgroup or sensitivity analysis was employed, while for studies without distinct clinical heterogeneity, a random effects model was carefully applied for the meta-analysis.

Results

Literature search results

Initially, 564 relevant studies were identified; ultimately 13 RCTs were included in the meta-analysis.^{1–13} The results of the literature screening process are shown in Figure 1.

Basic features and quality assessment of included studies

The characteristics of the included studies and the results of methodologic quality evaluation are presented in Table 1.

Meta-analysis results

Incidence of POCD. Ten RCTs reported the incidence of POCD on the first

postoperative day. There was no substantial heterogeneity between the studies (P = 0.60, $I^2 = 0\%$). A fixed effect model was therefore adopted for meta-analysis, and the results showed that the incidence of POCD in dexmedetomidine group was significantly lower than controls (relative risk, RR = 0.59, 95% CI 0.45–0.76, P<0.0001; Figure 2).

Seven RCTs reported the incidence of POCD after the first postoperative day. Again, we observed no substantial heterogeneity between the studies (P=0.36, $I^2=9\%$). We therefore adopted a fixed effect model for meta-analysis, and found that there was no significant difference in the incidence of POCD between the dexmedetomidine and the control groups (RR=0.66, 95% CI 0.45–0.98, P=0.04; Figure 3).

Postoperative MMSE score. Six RCTs reported MMSE score on the first post-operative day. A random effects model was employed for meta-analysis, and the results suggested that MMSE was significantly higher on the first postoperative day in the dexmedetomidine group than the control group (MD = 2.73, 95% CI 1.33–4.12, P < 0.00001; Figure 4). However, we identified one study (Guo et al., 2015) that accounted for substantial heterogeneity. After this study was excluded from the analysis, the MD was determined to be 2.12, and sensitivity analysis identified 95% CIs of 1.30 to 2.95 $(I^2 = 43\%).$

Analysis of publication bias: Funnel plot analysis. The funnel plot was symmetrical, suggesting that there was no publication bias (Figure 5). Further subgroup analyses, on the basis of the types of surgery and surgical sites, had little effect on the pooled results.

Discussion

As societies age, more and more elderly patients are undergoing surgery, and are

| e meta-analysis. |
|------------------|
| the |
| .⊑ |
| included |
| studies incl |
| s of the |
| of |
| Characteristics |
| <u> </u> |
| Table |

| Author (publication year) | Headcount | Grouping | Surgical setting | Surgical site | Jadad score |
|------------------------------|-----------|---|------------------------------------|--|----------------|
| Ding (2015) | 100 | Physiologic saline Dexmedatomidine | Laparoscopic radical prostatectomy | Prostate | S |
| Zhang (2014) | 80 | Physiologic saline | Laparoscopic surgery | Colon and rectum | 4 |
| Li (2015) | 100 | Dexmedetornidine Physiologic saline Dexmedatomidine | Laparoscopic cholecystectomy | Gall bladder | 4 |
| Mohamed (2014) | 50 | Physiologic saline | Abdominal surgery | Abdomen | 5 |
| Chen (2015) | 148 | Physiologic saline | Time-selection surgery | Fracture, prostate, gall bladder and rectal | m |
| Chen (2013) | 122 | Dexmedetomidine Physiologic saline Dovunderanidine | Laparoscopic cholecystectomy | Gall bladder | S |
| Guan (2015) | 06 | Physiologic saline Dexmedetomidine | Laparoscopic surgery | Abdomen | 4 |
| Guo (2015) | 149 | Ketamine Physiologic saline | Cancer surgery | Oral | c |
| Li (2014) | 180 | Dexmederomiaine Physiologic saline | Abdominal surgery | Abdomen | ſ |
| Liu (2015) | 88 | Dexmederomiaine Physiologic saline Dexmederomidine | Elective surgery | Abdomen | e |
| Meng (2016) | 40 | Physiologic saline Dexmediatromidine | Laparoscopic surgery | Rectal | ε |
| Peng (2012) | 80 | Physiologic saline Devmedetomidine | Prostate resection | Prostate | |
| Zhang (2013) | 120 | Physiologic saline Dexmedetomidine Ketamine Dexmedetomidine + ketamine Ketamine | Orthopaedic surgery | Orthopaedic | m |

Zhou et al.





Figure 1. Study flow diagram.

| | Dexmedetor | nidine | Contr | ol | | Risk Ratio | Risk Ratio |
|-----------------------------------|-----------------|----------|---------------------|-------|--------|--------------------|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% Cl | M-H, Fixed, 95% Cl |
| Chen 2013 | 9 | 59 | 17 | 63 | 13.2% | 0.57 [0.27, 1.17] | |
| Chen 2015 | 8 | 87 | 13 | 61 | 12.3% | 0.43 [0.19, 0.98] | |
| Ding 2015 | 11 | 50 | 17 | 50 | 13.6% | 0.65 [0.34, 1.24] | |
| Guan 2015 | 8 | 30 | 9 | 30 | 7.2% | 0.89 [0.40, 1.99] | |
| Li 2014 | 8 | 90 | 19 | 90 | 15.2% | 0.42 [0.19, 0.91] | |
| Li 2015 | 10 | 50 | 21 | 50 | 16.9% | 0.48 [0.25, 0.91] | |
| Liu 2015 | 1 | 34 | 8 | 45 | 5.5% | 0.17 [0.02, 1.26] | |
| Mohamed 2014 | 5 | 25 | 5 | 25 | 4.0% | 1.00 [0.33, 3.03] | |
| Zhang 2013 | 6 | 30 | 8 | 30 | 6.4% | 0.75 [0.30, 1.90] | |
| Zhang 2014 | 8 | 60 | 7 | 60 | 5.6% | 1.14 [0.44, 2.95] | |
| Total (95% CI) | | 515 | | 504 | 100.0% | 0.59 [0.45, 0.76] | • |
| Total events | 74 | | 124 | | | | |
| Heterogeneity: Chi ² = | 7.32, df = 9 (P | = 0.60); | I ² = 0% | | | F. | |
| Test for overall effect | Z = 4.06 (P < 1 | 0.0001) | | | | | 01 0.1 1 10 100 ours (experimental) Favours (control) |

Figure 2. Incidence of POCD on the first post-operative day.

| | Dexmedeto | midine | Contr | ol | | Risk Ratio | Risk Ratio |
|-----------------------------------|------------------|----------|---------------------|-------|--------|--------------------|--|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Fixed, 95% Cl | M-H, Fixed, 95% Cl |
| Ding 2015 | 9 | 50 | 12 | 50 | 24.7% | 0.75 [0.35, 1.62] | |
| Guan 2015 | 6 | 30 | 6 | 30 | 12.4% | 1.00 [0.36, 2.75] | |
| Liu 2015 | 0 | 42 | 0 | 42 | | Not estimable | |
| Mohamed 2014 | 6 | 25 | 5 | 25 | 10.3% | 1.20 [0.42, 3.43] | |
| Peng 2012 | 5 | 40 | 11 | 40 | 22.7% | 0.45 [0.17, 1.19] | |
| Zhang 2013 | 3 | 30 | 4 | 30 | 8.2% | 0.75 [0.18, 3.07] | |
| Zhang 2014 | 6 | 60 | 7 | 20 | 21.6% | 0.29 [0.11, 0.75] | |
| Total (95% CI) | | 277 | | 237 | 100.0% | 0.66 [0.45, 0.98] | • |
| Total events | 35 | | 45 | | | | |
| Heterogeneity: Chi ² = | 5.50, df = 5 (P | = 0.36); | I ² = 9% | | | | |
| Test for overall effect | Z = 2.08 (P = 1) | 0.04) | | | | | Favours [experimental] Favours [control] |



| | | detomi | | 1000 C | ontrol | | 2220202 | Mean Difference | Mean Difference |
|-----------------------------------|------------|---------------------|-----------|-----------|--------|-----------------------|---------|--------------------|---|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% Cl | IV, Random, 95% Cl |
| Chen 2015 | 25.86 | 4.1 | 87 | 23.29 | 4.59 | 61 | 14.9% | 2.57 [1.13, 4.01] | |
| Guan 2015 | 23.35 | 5.16 | 30 | 22.46 | 4.35 | 30 | 11.6% | 0.89 [-1.53, 3.31] | |
| Guo 2015 | 22.53 | 2.85 | 76 | 17.25 | 3.63 | 73 | 16.1% | 5.28 [4.23, 6.33] | |
| Li 2014 | 27.3 | 5.8 | 90 | 24.5 | 4.5 | 90 | 14.7% | 2.80 [1.28, 4.32] | |
| Li 2015 | 27.9 | 1.7 | 50 | 26.7 | 1.9 | 50 | 17.0% | 1.20 [0.49, 1.91] | - |
| Liu 2015 | 25.82 | 4.32 | 42 | 23.06 | 4.08 | 46 | 13.8% | 2.76 [1.00, 4.52] | |
| Meng 2016 | 26.4 | 4.5 | 20 | 23.1 | 2.8 | 20 | 11.9% | 3.30 [0.98, 5.62] | |
| Total (95% CI) | | | 395 | | | 370 | 100.0% | 2.73 [1.33, 4.12] | • |
| Heterogeneity: Tau ² = | 2.86; Chi | ² = 42.3 | 0, df = 6 | 6 (P < 0. | 00001 |); I ² = 8 | 6% | | |
| Test for overall effect: | Z = 3.83 (| P = 0.00 | 001) | | | | | - | -10 -5 0 5 10 urs (experimental) Favours (control) |

Figure 4. Mini-Mental State Examination score on the first post-operative day.




Figure 5. Funnel plot.

therefore exposed to the risk of POCD. The incidence of POCD in elderly patients is high, and there is increasing interest in identifying strategies to prevent POCD, given its consequences. The cause of POCD is still uncertain. Some investigators¹⁴ have reported that the main symptoms of POCD include decreased memory and concentration, and degeneration of intelligence. Mild POCD may prolong hospitalization and increase the costs of care, but changes in memory, intelligence, verbal ability, personality and sociability and may impair patients' ability to engage with work and life activities. Severe POCD may cause patients to lose the ability to speak, bring about personality change and AD, and impair their capacity for self-care; the consequences for the quality of life of patients, their carers and society is profound.

Although POCD is common, its pathophysiologic mechanism is poorly understood. Several risk factors have, however, been identified, including duration of anaesthesia, need for reoperation, old age, postoperative infection, postoperative respiratory complications and low educational level.¹⁵

Our meta-analysis suggested that dexmedetomidine can significantly reduce the incidence of early POCD in elderly patients and improve postoperative MMSE score. It acts at the locus coeruleus in the brain stem, which contains the highest concentration of $\alpha 2$ adrenoceptors. By regulating neurotransmitter release, the locus coeruleus is critical for coordination of waking and sleeping, and is the source of noradrenergic pathways from the medulla oblongata to the spinal cord. By acting on $\alpha 2$ adrenoceptors in the brain and spinal cord, dexmedetomidine inhibits neuronal discharge, thus inhibiting the effects of sympathetic nervous system activity. An association between POCD and the inflammatory response has also been reported. Cibelli and colleagues examined whether systemic inflammation in response to surgical trauma gives rise to subsequent memory impairment and hippocampal inflammation in a mouse model of orthopaedic surgery, and found that inflammation played a critical role in the pathogenesis of POCD and could be reversed by minocycline, a nonspecific inhibitor of inflammation.¹⁶ The trauma of surgery stimulates the immune cascade and the release of inflammatory mediators, which may then provoke POCD. A number of animal experiments have shown that dexmedetomidine can reduce inflammation,17,18 which may also explain how it reduces the incidence of POCD.

Dexmedetomidine can reduce cerebral blood flow by reducing cerebral perfusion pressure, and even during hyperventilation, also can reduce cerebral oxygen saturation without affecting oxygen supply to the brain. Furthermore, it can act as a neuroprotectant in areas of localized cerebral ischemia or tissue hypoxia.¹⁹

There is a body of opinion that POCD is provoked by intraoperative arterial hypotension, excessive doses of anaesthetic drugs and increased serum cortisol concentration.²⁰ Dexmedetomidine, when administered as an adjunct to anaesthesia, promotes hemodynamic stability,^{21,22} while reducing the dose of intraoperative anaesthetic and analgesic drugs.^{22,23} These properties could also explain its therapeutic benefits in preventing POCD.

Sato et al.²⁴ reported that dexmedetomidine confers its neuroprotective effects by mitigating injury to neurons in the hippocampal CA1 region in a rat model of cerebral ischemia. In neonatal rats.²⁵ dexmedetomidine can improve postanaesthetic neurocognitive function by diminishisoflurane-induced injury to ing the hippocampus, thalamus and cortex. Several other previous studies also have reported this phenomenon in rodents.^{26–28} If isoflurane-induced neuroapoptosis emerges as a problem in clinical practice, co-administration of dexmedetomidine with isoflurane may reduce neurotoxicity.

Although factors associated with anaesthesia and surgery have both been identified as risk factors for POCD, little is known about surgery-related causes. Only cardiac surgery has been identified as a risk factor, and there is no strong evidence that other surgical procedures or techniques influence the incidence of POCD. In contrast, regional anaesthesia is associated with a reduced incidence of POCD compared with general anaesthesia.

Our study had some limitations. The number of studies and the combined sample size were relatively small, and the doses and methods of administration of dexmedetomidine given to patients varied substantially. The included studies' inclusion and exclusion criteria, and consequently the characteristics of the patient cohorts, were also varied, which might have resulted in heterogeneity.

In summary, dexmedetomidine appears to reduce significantly the risk of early POCD in elderly patients after general anaesthesia, and improve postoperative MMSE score.

Author Contributions

Conception and design of the study: Chengmao Zhou, Yu Zhu, Lin Ruan. Search strategy: Chengmao Zhou, Yu Zhu, Zhen Liu, Lin Ruan. Data analysis: Chengmao Zhou, Yu Zhu, Lin Ruan. Contributed materials or analysis tools: Chengmao Zhou, Yu Zhu, Lin Ruan. Wrote the paper: Chengmao Zhou, Yu Zhu, Zhen Liu, Lin Ruan.

Acknowledgements

The authors are grateful to You-Jing Luo, MD for her extensive support throughout the drafting and approval of the article, which substantially improved the quality of the manuscript.

Declaration of conflicting interests

The Authors declare that there is no conflict of interest.

Funding

This research received no specific grant from any funding agency in the public, commercial or notfor-profit sectors.

References

- 1. Li Y, He R, Chen S, et al. Effect of dexmedetomidine on early postoperative cognitive dysfunction and peri-operative inflammation in elderly patients undergoing laparoscopic cholecystectomy. *Exp Ther Med* 2015; 10: 1635–1642.
- Chen W, Liu B, Zhang F, et al. The effects of dexmedetomidine on post-operative cognitive dysfunction and inflammatory factors in senile patients. *Int J Clin Exp Med* 2015; 8: 4601–4605.
- Ding L, Zhang H, Mi W, et al. Effects of dexmedetomidine on anesthesia recovery period and postoperative cognitive function of patients after robot-assisted laparoscopic radical cystectomy. *Int J Clin Exp Med* 2015; 8: 11388–11395.
- 4. Zhang Y, Xing Z, Xu Y, et al. Effects of different doses of dexmedetomidine on

cognitive dysfunction in elderly patients early after laparoscopic surgery for colorectal cancer. *Nan Fang Yi Ke Da Xue Xue Bao* 2014; 34: 743–746. [in Chinese, English Abstract].

- S M and Ar S. The effect of dexmedetomidine on the incidence of postoperative cognitive dysfunction in elderly patients after prolonged abdominal surgery. *Egyptian Journal of Anaesthesia* 2014; 30: 331–338.
- 6. Meng J, Zhang H and Yu YH. The influence of dexmedetomidine for elderly patients with laparoscopic surgery right cerebral oxygen saturation and postoperative cognitive function. *Journal of Tianjin Medical University* 2016; 1: 66–68.
- Guan YJ, Chen Y, Su SX, et al. Influence of subanesthetic dose Ketamine and loading dose dexmedetomidine on postoperative cognitive dysfunction in the elderly patients. *China Medical Herald* 2015; 3: 61–63, 72.
- Liu YY, Wan X, Liu Min, et al. Hydrochloric acid dexmedetomidine on early cognitive function after surgery for elderly patients. *Herald of Medicine* 2015; 34: 214–217.
- Li YX and Dai HC. Effect of dexmedetomidine on cognitive dysfunction in elderly patients receiving abdominal operation in general anesthesia. *The Journal of Clinical Anesthesiology* 2014; 30: 964–967.
- Chen J, Yan J and Han X. Dexmedetomidine may benefit cognitive function after laparoscopic cholecystectomy in elderly patients. *Exp Ther Med* 2013; 5: 489–494.
- Peng ZQ, Zhang W and Chu QJ. Effects of dexmedetomidine on early postoperation cognitive function after transurethral resection of prostate in elderly patient. *The Journal of Clinical Anesthesiology* 2013; 29: 945–947.
- Zhang XD, Pu MH, Wang YJ, et al. Influence of sub-anesthetic dose of ketamine and dexmedetomidine on early postoperative cognitive function in elderly orthopedic patients under total intravenous anesthesia. *Journal of Jilin University (Medicine Edition)* 2013; 39: 133–137.
- 13. Guo Y, Sun L and Zhang J. Preventive effects of low-dose dexmedetomidine on postoperative cognitive function and

recovery quality in elderly oral cancer patients. *Int J Clin Exp Med* 2015; 8: 16183–16190.

- Rasmussen LS. Defining postoperative cognitive dysfunction. *Eur J Anaesthesiol* 1998; 15: 761–764.
- Moller JT, Cluitmans P, Rasmussen LS, et al. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International study of post-operative cognitive dysfunction. *Lancet* 1998; 351: 857–861.
- Cibelli M, Fidalgo AR, Terrando N, et al. Role of interleukin-1beta in postoperative cognitive dysfunction. *Ann Neurol* 2010; 68: 360–368.
- Taniguchi T, Kidani Y, Kanakura H, et al. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin induced shock in rats. *Crit Care Med* 2004; 32: 1322–1326.
- Sezer A, Memis D, Usta U, et al. The effect of dexmedetomidine on liver histopathology in a rat sepsis model: an experimental pilot study. *Ulus Travma Acil Cerrahi Derg* 2010; 16: 108–112.
- Ma D, Rajakumaraswamy N and Maze M. alpha2-Adrenoceptor agonists: shedding light on neuroprotection? *Br Med Bull* 2005; 71: 77–92.
- Rasmussen LS, O'Brien JT, Silverstein JH, et al. Is peri-operative cortisol secretion related to post-operative cognitive dysfunction? *Acta Anaesthesiol Scand* 2005; 49: 1225–1231.
- 21. Guler G, Akin A, Tosun Z, et al. Single-dose dexmedetomidine attenuates airway and

circulatory reflexes during extubation. *Acta Anaesthesiol Scand* 2005; 49: 1088–1091.

- Kaur M and Singh PM. Current role of dexmedetomidine in clinical anesthesia and intensive care. *Anesth Essays Res* 2011; 5: 128–133.
- Khan ZP, Munday IT, Jones RM, et al. Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions. *Br J Anaesth* 1999; 83: 372–380.
- Sato K, Kimura T, Nishikawa T, et al. Neuroprotective effects of a combination of dexmedetomidine and hypothermia after incomplete cerebral ischemia in rats. *Acta Anaesthesiol Scand* 2010; 54: 377–382.
- Sanders RD, Xu J, Shu Y, et al. Dexmedetomidine attenuates isofluraneinduced neurocognitive impairment in neonatal rats. *Anesthesiology* 2009; 110: 1077–1085.
- Goyagi T, Nishikawa T, Tobe Y, et al. The combined neuroprotective effects of lidocaine and dexmedetomidine after transient forebrain ischemia in rats. *Acta Anaesthesiol Scand* 2009; 53: 1176–1183.
- 27. Kuhmonen J, Haapalinna A and Sivenius J. Effects of dexmedetomidine after transient and permanent occlusion of the middle cerebral artery in the rat. *J Neural Transm* (*Vienna*) 2001; 108: 261–271.
- Kuhmonen J, Pokorný J, Miettinen R, et al. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. *Anesthesiology* 1997; 87: 371–377.